Changing patterns of invasive meningococcal disease and future immunization strategies
Invasive meningococcal disease (IMD) is a life-threatening disease caused by Neisseria meningitidis and has high mortality rates. Survivors often exhibit long-term sequelae and reduced life expectancy. Disease incidence is highest in infants and toddlers, with a resurgence of cases in adolescents an...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2023-01-01
|
| Series: | Human Vaccines & Immunotherapeutics |
| Subjects: | |
| Online Access: | http://dx.doi.org/10.1080/21645515.2023.2186111 |
| _version_ | 1797673097983164416 |
|---|---|
| author | Muhamed-Kheir Taha Rafik Bekkat-Berkani Véronique Abitbol |
| author_facet | Muhamed-Kheir Taha Rafik Bekkat-Berkani Véronique Abitbol |
| author_sort | Muhamed-Kheir Taha |
| collection | DOAJ |
| description | Invasive meningococcal disease (IMD) is a life-threatening disease caused by Neisseria meningitidis and has high mortality rates. Survivors often exhibit long-term sequelae and reduced life expectancy. Disease incidence is highest in infants and toddlers, with a resurgence of cases in adolescents and older adults (>50 years of age). Substantial heterogeneity exists in the recommendations of meningococcal vaccines included in National Immunization Programs (NIPs) across countries. Recommendations are usually based on infant/toddler immunization, with some countries recommending immunization only for toddlers. While existing recommendations have led to a reduced incidence of IMD in children <5 years of age, there has been an increase in cases among adolescents and older adults. Currently, older adults are not included in the recommendations. The higher healthcare burden and the economic costs associated with IMD in these age groups suggest that it is time to consider including adolescents and older adults in NIPs to protect against IMD caused by the five most prevalent serogroups. Currently, the lack of equity of access to vaccines in the immunization programs is a glaring gap in the betterment of public health, and a broader meningococcal strategy is recommended to provide optimal protection for all age groups. |
| first_indexed | 2024-03-11T21:39:40Z |
| format | Article |
| id | doaj.art-508f76067ab740b8b181d5f7404edcb8 |
| institution | Directory Open Access Journal |
| issn | 2164-5515 2164-554X |
| language | English |
| last_indexed | 2024-03-11T21:39:40Z |
| publishDate | 2023-01-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Human Vaccines & Immunotherapeutics |
| spelling | doaj.art-508f76067ab740b8b181d5f7404edcb82023-09-26T13:25:48ZengTaylor & Francis GroupHuman Vaccines & Immunotherapeutics2164-55152164-554X2023-01-0119110.1080/21645515.2023.21861112186111Changing patterns of invasive meningococcal disease and future immunization strategiesMuhamed-Kheir Taha0Rafik Bekkat-Berkani1Véronique Abitbol2National Reference Centre for Meningococci and Haemophilus InfluenzaGSKGSKInvasive meningococcal disease (IMD) is a life-threatening disease caused by Neisseria meningitidis and has high mortality rates. Survivors often exhibit long-term sequelae and reduced life expectancy. Disease incidence is highest in infants and toddlers, with a resurgence of cases in adolescents and older adults (>50 years of age). Substantial heterogeneity exists in the recommendations of meningococcal vaccines included in National Immunization Programs (NIPs) across countries. Recommendations are usually based on infant/toddler immunization, with some countries recommending immunization only for toddlers. While existing recommendations have led to a reduced incidence of IMD in children <5 years of age, there has been an increase in cases among adolescents and older adults. Currently, older adults are not included in the recommendations. The higher healthcare burden and the economic costs associated with IMD in these age groups suggest that it is time to consider including adolescents and older adults in NIPs to protect against IMD caused by the five most prevalent serogroups. Currently, the lack of equity of access to vaccines in the immunization programs is a glaring gap in the betterment of public health, and a broader meningococcal strategy is recommended to provide optimal protection for all age groups.http://dx.doi.org/10.1080/21645515.2023.2186111adolescent vaccinationage distributioninvasive meningococcal diseaseneisseria meningitidisolder adultsvaccination strategiesvaccine equity |
| spellingShingle | Muhamed-Kheir Taha Rafik Bekkat-Berkani Véronique Abitbol Changing patterns of invasive meningococcal disease and future immunization strategies Human Vaccines & Immunotherapeutics adolescent vaccination age distribution invasive meningococcal disease neisseria meningitidis older adults vaccination strategies vaccine equity |
| title | Changing patterns of invasive meningococcal disease and future immunization strategies |
| title_full | Changing patterns of invasive meningococcal disease and future immunization strategies |
| title_fullStr | Changing patterns of invasive meningococcal disease and future immunization strategies |
| title_full_unstemmed | Changing patterns of invasive meningococcal disease and future immunization strategies |
| title_short | Changing patterns of invasive meningococcal disease and future immunization strategies |
| title_sort | changing patterns of invasive meningococcal disease and future immunization strategies |
| topic | adolescent vaccination age distribution invasive meningococcal disease neisseria meningitidis older adults vaccination strategies vaccine equity |
| url | http://dx.doi.org/10.1080/21645515.2023.2186111 |
| work_keys_str_mv | AT muhamedkheirtaha changingpatternsofinvasivemeningococcaldiseaseandfutureimmunizationstrategies AT rafikbekkatberkani changingpatternsofinvasivemeningococcaldiseaseandfutureimmunizationstrategies AT veroniqueabitbol changingpatternsofinvasivemeningococcaldiseaseandfutureimmunizationstrategies |